Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEAR Stroke: Eptifibatide + rt-PA in Acute Ischemic Stroke
NCT00250991Phase 2Completed
- Sponsor
- University of Cincinnati
- Start
- Jul 2003
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of eptifibatide in ischemic stroke (2 arms), sponsored by University of Cincinnati. Primary endpoints: Incidence of Symptomatic Intracranial Hemorrhage at 36 hours and Incidence of Early Neurological Improvement (NIHSS <= 2) at 24 hours. Started Jul 2003; status: completed.
02
Drugs
eptifibatide
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT00250991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00250991.